{"id":2487,"date":"2025-12-12T08:40:25","date_gmt":"2025-12-12T01:40:25","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=2487"},"modified":"2025-12-23T11:25:40","modified_gmt":"2025-12-23T04:25:40","slug":"korean-second-generation-varicella-vaccine-with-outstanding-advantages-gains-widespread-trust","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/korean-second-generation-varicella-vaccine-with-outstanding-advantages-gains-widespread-trust","title":{"rendered":"Korean Second-Generation Varicella Vaccine with Outstanding Advantages Gains Widespread Trust"},"content":{"rendered":"

On November 1, 2025, in Ho Chi Minh City, and on December 6, 2025, in Da Nang, Naviva Group, in collaboration with GC Biopharma (South Korea), organized a scientific conference entitled \u201cAdvancements in Varicella Prevention Using the MAV\/06 Strain.\u201d<\/i><\/strong><\/span><\/p>\n

\"\"<\/a><\/p>\n

A representative of GC Biopharma shared updates on quality improvements in the second-generation MAV\/06 strain varicella vaccine.<\/span><\/p>\n

The event aimed to provide the latest scientific information on recent advancements in varicella prevention using the MAV\/06 vaccine strain.<\/span><\/p>\n

At the conference, MSc., MD. Nguyen Hien Minh \u2013 Deputy Head of the Vaccination Unit at the University Medical Center Ho Chi Minh City \u2013 presented a specialized report titled <\/span>\u201cEnhancing the Quality of the MAV\/06 Strain Varicella Vaccine.\u201d<\/span><\/i><\/span><\/p>\n

According to Dr. Nguyen Hien Minh, the MAV\/06 strain vaccine has been used in South Korea since 1993 and has been incorporated into the country\u2019s National Expanded Program on Immunization.<\/span><\/p>\n

The first-generation vaccine has been licensed for use in more than 30 countries, with over 30 million doses distributed worldwide. Particularly in Vietnam, the vaccine has been in use since 2008 and has consistently demonstrated both efficacy and safety.<\/span><\/p>\n

The second-generation MAV\/06 strain varicella vaccine builds upon the foundation of the first generation and incorporates significant manufacturing improvements, including the use of the WHO-recommended MRC-5 human diploid cell line, a fully automated and closed production process, and antibiotic-free manufacturing.<\/span><\/p>\n

Overview of the scientific conference on advancements in varicella prevention.<\/span><\/i><\/span><\/p>\n

The second-generation vaccine has been evaluated and licensed in the international market:<\/span><\/p>\n